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SUMMARY
During pregnancy, maternal regulatory T cells (Tregs)
are important in establishing immune tolerance to
invading fetal extravillous trophoblasts (EVTs).
CD25HIFOXP3+ Tregs are found at high levels in
decidual tissues and have been shown to suppress
fetus-specific and nonspecific responses. However,
limited data are available on additional decidual
Treg types and the mechanisms by which they are
induced. This study investigated three distinct
decidual CD4+ Treg types in healthy pregnancies
with a regulatory phenotype and the ability to sup-
press T cell responses: CD25HIFOXP3+, PD1HIIL-
10+, and TIGIT+FOXP3dim. Moreover, co-culture of
HLA-G+ EVTs or decidual macrophages with blood
CD4+ T cells directly increased the proportions
of CD25HIFOXP3+ Tregs compared to T cells
cultured alone. EVTs also increased PD1HI Tregs
that could be inhibited by HLA-C and CD3 anti-
bodies, suggesting an antigen-specific induction.
The presence of distinct Treg types may allow
for the modulation of a variety of inflammatory re-
sponses in the placenta.
INTRODUCTION
During pregnancy, CD4+CD25HIFOXP3+ regulatory T cells
(Tregs) are found at high levels in decidual tissue and have
the ability to suppress fetus-specific and nonspecific re-
sponses (Erlebacher, 2013; Tilburgs et al., 2008). Most inter-
estingly, HLA-C mismatched pregnancies (where the fetus
and extravillous trophoblasts (EVTs) express an HLA-C allo-
type that the mother does not have) had increased levels of
functional CD4+CD25HI Tregs in decidua, compared to
HLA-C matched pregnancies (Tilburgs et al., 2009). Further-
more, in vitro co-culture of naive CD4+ T cells with EVTs
directly increased the proportion of CD4+FOXP3+ Tregs,
compared to CD4+ T cells cultured alone (Du et al., 2014;
Svensson-Arvelund et al., 2015; Tilburgs et al., 2015). This
suggests that maternal T cells may specifically recognize fetal
HLA-C, but its expression on EVTs promotes immune toler-
ance. The importance of maternal immune tolerance for fetal
HLA-C is further illustrated by a recent study suggesting that
HLA-C antibodies may contribute to the etiology of miscar-
riage (Meuleman et al., 2016). The proportion of circulating
FOXP3+ Tregs was shown to be diminished in maternal blood
obtained after spontaneous preterm birth (SPTB) (Kisielewicz
et al., 2010; Koucky´ et al., 2014; Schober et al., 2012), pre-
eclampsia (PE) (Steinborn et al., 2008; Wagner et al., 2016)
and in decidual tissue obtained after recurrent spontaneous
miscarriage (Inada et al., 2015, 2013). Furthermore, clonally
expanded CD4+CD25HICD127–CD45RA– Treg populations
were observed in healthy term pregnancy decidua, and failure
of this clonal expansion may be related to development of pre-
eclampsia (Tsuda et al., 2018). The importance of Tregs was
also demonstrated in murine pregnancy models (Aluvihare
et al., 2004; Moldenhauer et al., 2009; Xin et al., 2014; Zen-
clussen et al., 2005). Depletion of CD25+ Tregs during alloge-
neic matings, but not syngeneic matings, resulted in an
increased resorption rate (Aluvihare et al., 2004). Besides high-
lighting the role for Tregs, this also demonstrated that in the
absence of Tregs, effector cells cause immunologic rejection
of allogeneic fetal or placental tissues. A more recent murine
study demonstrated that FOXP3+ Tregs with specificity to
paternal antigens were generated extrathymically and accu-
mulated in the placenta. In this study, females with impaired
ability for extrathymic Treg induction showed increased fetal
resorption rates and had increased influx of immune cells to
Cell Reports 27, 2537–2547, May 28, 2019 ª 2019 The Authors. 2537
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the placenta in allogeneic matings, but not syngeneic matings
(Samstein et al., 2012). Other pathways and molecules have
been demonstrated to play a role in Treg induction during
pregnancy, including the blockade of the PD1-PDL1 pathway
that led to reduced decidual CD25+FOXP3+ Treg numbers
and increased embryo resorption in mice, which could be
abrogated by adoptive CD25+FOXP3+ Treg transfer (D’Addio
et al., 2011). This demonstrates the importance of PD1-PDL1
for decidual Treg induction. However, specific factors that
contribute to diminished decidual Treg numbers or function
during pregnancy complications have not been identified in
human pregnancy.
Thus far, research on the role of Tregs in human pregnancy
has mainly focused on FOXP3+ Tregs (Dimova et al., 2011; In-
ada et al., 2015, 2013; Kisielewicz et al., 2010; Koucky´ et al.,
2014; Mjo¨sberg et al., 2010; Nadkarni et al., 2016; Schober
et al., 2012; Tilburgs et al., 2008; Tsuda et al., 2018), while
other types of FOXP3- Tregs have not been studied in as
much detail. Most importantly, only a handful of studies pro-
vide functional analysis of peripheral blood (Steinborn et al.,
2008; Wagner et al., 2016) and decidual Tregs (Tilburgs
et al., 2008, 2009) during human pregnancy. FOXP3, in com-
bination with high expression of CD25 and HELIOS and the
absence of CD127 expression, primarily identifies natural
Tregs (nTregs), although whether HELIOS is a defining marker
for human nTregs remains controversial. The nTregs are
generated in the thymus, are specific for self-antigens, and
are responsible for preventing anti-self (autoimmune) re-
sponses (Miyara et al., 2009; Sakaguchi et al., 2001). In
contrast, induced Tregs (iTregs) are generated in the periph-
ery and can be specific for a large variety of antigens,
including allo-antigens and viral-antigens (Belkaid, 2007;
Chong and Alegre, 2014; Vignali et al., 2008). A well-charac-
terized type of iTregs are Tr1 cells that secrete high levels of
IL-10; express PD1; co-express CD49b and LAG3, but do
not express FOXP3; and are important in the control of allo-
immune responses (Gagliani et al., 2013; Roncarolo and Bat-
taglia, 2007). Other iTregs include TIGIT+ cells that modulate
antigen-presenting cells (APC) through interaction with
CD155 on APCs and Tr35 cells that function through secretion
of IL-35, an immune suppressive cytokine (Collison et al.,
2007; Joller et al., 2014). A large variety of other markers
have been used to identify distinct iTreg populations
(including but not limited to FOXP3, CD25, GITR, TIM3,
CD39, LRRC32 [also known as GARP], LAP, and CCR8) (An-
derson et al., 2016; Collison et al., 2010; Deaglio et al.,
2007; Shevach and Thornton, 2014). None of these markers
are truly specific for iTregs, as they can also be expressed
on activated T cells. Thus, to identify iTregs, functional assays
are required to demonstrate their capacity to suppress im-
mune responses such as proliferation, cytokine secretion,
and cytotoxicity (Meng et al., 2016; Vignali et al., 2008). In
this study, we provide extensive phenotypic and functional
characterization of three types of decidual CD4+ Tregs in
uncomplicated human pregnancies and investigate the ability
of HLA-G+ HLA-C+ EVTs and decidual macrophages, the
main APCs at the maternal-fetal interface, to increase Treg
proportions.
RESULTS
Distinct CD4+ T Cell Types with a Regulatory Phenotype
Are Present in Decidual Tissue
FACS analysis on freshly isolated peripheral blood CD4+
T cells (CD4+ pTs) and decidual CD4+ T cells (CD4+ dTs) iso-
lated from first-trimester decidua (gestational age 6–12 weeks)
and term placenta decidua basalis (d.basalis) and decidua pa-
rietalis (d.parietalis) (gestational age > 37 weeks) was per-
formed to determine cell surface expression of CD45, CD4,
CD25, PD1, TIGIT, CD127, CD45RA, CD49b, and LAG3 and
intracellular expression of FOXP3 and HELIOS. A clear popu-
lation of activated nTregs was identified in all tissues based on
the high expression of CD25, FOXP3, and HELIOS and the
lack of CD45RA and CD127 (Figure 1; Figures S1AS1D)
(Miyara et al., 2009). While the percentage of FOXP3+ and
HELIOS+ cells within this CD25HI population significantly
decreased in term pregnancy decidua, the proportion of
HELIOS+ cells within CD25HIFOXP3+ cells remained relatively
stable (Figure 1D, right panel). A second T cell population was
identified based on the high expression of PD1, the lack of
FOXP3 and HELIOS, and low CD25. LAG3 and CD49b were
not expressed by CD4+ dTs. While both CD25HI and PD1HI
cells co-expressed high levels of TIGIT, a third population of
CD4+ dTs also expressed high levels of TIGIT and low levels
of FOXP3, HELIOS, PD1, and CD25 (Figure 1; Figures
S1AS1D). FOXP3 expression in TIGIT+ cells was sig-
nificantly lower than in CD25HI cells (Figure S1E). The
t-Distributed Stochastic Neighbor Embedding (t-SNE) analysis
confirmed the separation of these three T cell populations
(Figure S2) that hereafter will be named (1) CD25HIFOXP3+,
(2) PD1HI, and (3) TIGIT+. These three CD4+ T cell types
were purified by FACS sort and analyzed for their ability to
produce the pro- and anti-inflammatory cytokines IFNɣ, IL-2,
and IL-10 upon phorbol 12-myristate 13-acetate (PMA)/Iono-
mycin stimulation. PD1HI T cells from all tissues expressed
the highest levels of IL-10 and co-expressed IFNg (Figure S3),
suggesting a resemblance to Tr1 cells (Gagliani et al., 2013).
CD25HIFOXP3+ cells of all tissue compartments expressed
the lowest levels of IL-10, IFNg, and IL- 2, whereas TIGIT+
cells expressed high levels of IFNg and IL-2 and low levels
of IL-10. A limitation of this study is the lack of clinical infor-
mation on the blood and tissues used for experiments that
may have impacts on Treg phenotypes and contribute to the
observed variation in Treg proportions. However, a previous
report did not find an influence of clinical variables such
as mode of delivery and fetal sex on the presence of
CD4+CD25dim-activated T cells and CD4+CD25HIFOXP3+
Tregs in decidual tissues of term pregnancy (Tilburgs et al.,
2009).
CD25HIFOXP3+, PD1HI, and TIGIT+ Suppress
Proliferation of CD4+ and CD8+ Teff Cells
To determine the capacity of CD25HIFOXP3+, PD1HI, and
TIGIT+ T cells to suppress proliferation of effector T cells
(Teffs), carboxyfluorescein succinimidyl ester (CFSE)-labeled
CD4+ or CD8+ Teffs were stimulated with anti-CD3 and
-CD28 beads in the presence or absence of sample-matched
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Tregs for 4 days in a 1:2 Treg to Teff ratio. CFSE profiles were
analyzed to determine the percentage of undivided cells
(generation 0) and the average number of divisions per cell
(division index) within the CD4+ and CD8+ Teffs cultured with
and without Tregs (Figure 2A). All three CD4+ Treg types in
decidual samples of 6–12 weeks suppressed proliferation of
CD4+ Teffs. This is illustrated by the significant increase in
the percentage of undivided cells (Figure 2B), and a significant
decrease of the division index (Figure 2E) upon co-culture of
Tregs and Teffs, compared to stimulated Teff cultured alone.
Additionally, purified PD1dim cells from 6-12 week decidual tis-
Figure 1. Three Distinct CD4+ T Cell Popu-
lations Express Treg-Associated Markers
(A and B) Representative FACS plots (A) and
percentages (B) of CD25HI, PD1HI, and TIGIT+
cells within CD4+ T cells in blood, decidua
6–12 weeks, d.basalis >37 weeks, and d.parietalis
>37 weeks.
(C and D) Representative FACS plots (C) and
percentages (D) of FOXP3+ and HELIOS+ cells
within the four CD4+ T cell types and HELIOS+
cells within CD25HIFOXP3+ cells in blood, decidua
6–12 weeks, d.basalis >37 weeks, and d.parietalis
>37 weeks (n = 8–10).
Bars represent median and interquartile range;
*p < 0.05, **p < 0.01 and ***p < 0.001.
See also Figures S1S3.
sues did not suppress proliferation of
CD4+ T cells (Figure S4A). CD25HI
FOXP3+ T cells also suppressed prolifer-
ation of sample-matched CD8+ Teffs,
whereas PD1HI and TIGIT+ cells did not
consistently reduce CD8+ Teff prolifera-
tion (Figures 2C and 2F). Analysis of the
three T cell populations from term
placenta d.parietalis demonstrated that
these cells had a reduced capacity
to suppress CD4+ Teff proliferation,
compared to their first-trimester coun-
terparts (Figures 2D and 2G), whereas
peripheral blood CD25HI and PD1HI, but
not TIGIT+ cells, suppressed prolifera-
tion of CD8+ Teffs (Figures S4BS4D).
To determine if IL-10 secretion by
PD1HI Tregs is their predominant mecha-
nism to suppress proliferation of CD4+
Teffs, as was previously shown for Tr1
cells (Gagliani et al., 2013; Roncarolo
and Battaglia, 2007), anti-IL-10R block-
ing antibodies or immunoglobulin G
(IgG) control antibodies were added to
anti-CD3 and -CD28 stimulated CFSE-
labeled CD4+ Teffs cultured alone or
with sample-matched CD25HI or PD1HI
cells. Indeed, addition of IL-10R anti-
bodies abrogated the suppressive ca-
pacity of PD1HI cells but not of the
CD25HI cells that were added in parallel control cultures
(Figure 2H).
CD25HIFOXP3+ and PD1HI Tregs Influence Cytokine
Production of CD4+ and CD8+ Teffs
Next, the capacity of decidual CD25HIFOXP3+, PD1HI, and
TIGIT+ Tregs to influence production of pro- and anti-inflamma-
tory cytokines byCD4+ andCD8+ Teffs was investigated. CFSE-
labeled CD4+ Teffs and CD45-Alexa700 labeled CD8+ Teffs
were cultured with or without sample matched Tregs in a 1:1:1
CD4 Teff: CD8 Teff: Treg ratio and stimulated with anti-CD3
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and -CD28. At day three, the cells were restimulated with PMA
and Ionomycin for 6h in the presence of GolgiStop for the last
4h. CD4+ Teffs, CD8+ Teffs, and Tregs were identified (Fig-
ure S5A) and analyzed for the presence of intracellular cytokines
IFNɣ, TNFɑ, and IL-10 (Figure S5B). Addition of CD25HI cells
significantly decreased the percentage of IFNɣ+ and TNFɑ+
CD4+ and IFNɣ+ CD8+ Teffs (Figures 3A,3B, and 3D). Addition
of PD1HI cells significantly increased the percentage of IL-10+
CD4+ and CD8+ Teffs (Figures 3C and 3F) but also increased
the percentage of IFNɣ+ CD8+ Teffs (Figure 3D). TIGIT+ cells
did not consistently change the production of cytokines by
CD4+ or CD8+ Teffs (Figure 3). Analysis of cytokine production
by Tregs themselves confirmed the overall low expression of cy-
tokines by CD25HI cells and high expression of IL-10 by PD1HI
cells (Figure S5C). Thus, besides suppressing Teff proliferation,
both CD25HI and PD1HI Tregs also modulated the production
of cytokines by Teffs.
CD25HIFOXP3+, PD1HI, and TIGIT+ Tregs from Decidua
and Blood Express Distinct Transcriptional Profiles
To further investigate the molecular mechanisms the three
Treg types may utilize to modulate T cell proliferation and cyto-
Figure 2. Decidual Tregs Suppress Prolifer-
ation of Teffs
(A) CFSE dilution of 6-12-week decidual CD4+
Teffs (upper panel) and CD8+ Teffs (lower panel)
stimulated with anti-CD3/28 and co-cultured with
or without CD25HI, PD1HI, or TIGIT+ Tregs during
4 days in a 1:2, Treg:Teff ratio. Percentages of the
undivided Teffs are shown.
(B–G) Fold change (FC) in the percentage of
undivided cells (B–D) and in the division index
(E–G) after the addition of CD25HI, PD1HI, or
TIGIT+ Tregs, compared to CD4+ Teffs 6–12
weeks (B and E), CD8+ Teffs 6–12weeks (C and F),
and CD4+ Teffs >37 weeks (D and G) cultured
alone.
(H) Addition of IL-10R blocking antibodies to
Teffs +PD1HI but not Teffs +CD25HI cultures inhibit
suppression of proliferation, measured by FC in
percentage of undivided cells, compared to iso-
type control cultures. Bars represent median and
interquartile range;
In (B)–(G): n = 7–11; (H): n = 3–4; *p < 0.05, **p <
0.01 and ***p < 0.001; values > 1 for FC % undi-
vided cells and < 1 for FC division index represent
suppression of proliferation. Division index reflects
the number of divisions per cell as calculated in
FlowJO v7.6.5.
See also Figure S4.
kine production, RNA was isolated from
CD25HIFOXP3+, PD1HI, and TIGIT+
Tregs purified from peripheral blood,
first-trimester decidua (6–12 weeks),
and term pregnancy d.parietalis (>37
weeks). The BioMark Fluidigm 96x96
QPCR chip was used to detect gene
expression. Sixty-six primer pairs had
detectable CT values and melting curves
(gene and primer list are included in Table S1). CT values
were normalized against GAPDH (DCT), and the fold change
(FC) was calculated relative to the median DCT of the
blood CD4+ Teffs. Expression levels of CD25, FOXP3, PD1,
and TIGIT confirmed the purity of the Treg fractions (Fig-
ure S6A). K-means cluster analysis of gene expression in
the four T cell populations visualized two separate gene
clusters in blood and decidua. Cluster I identified a set
of genes, including CD25, FOXP3, TIGIT, CD39, LRRC32
(GARP), ST2, BATF, and CCR8, which are highly expressed
by CD25HIFOXP3+, low in PD1HI, and intermediate in TIGIT+
Tregs (Figure 4A). Cluster II identified a set of genes, including
PD1, IFNɣ, IL-10, CCR5, and CXCR3, that are upregulated
by PD1HI Tregs (Figure 4B). Heatmaps depicting the dif-
ferentially expressed genes identified in these clusters are
shown (Figures 4C4E). These data further support that
CD25HIFOXP3+, PD1HI, and TIGIT+ are separate Treg types
that may utilize distinct molecular mechanisms of immune
modulation.
Additional K-means cluster analysis revealed several key reg-
ulatory genes that differ throughout gestation and between
decidual and blood Tregs (Figures S6B and S6C). Decidual
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CD25HIFOXP3+ Tregs show increased expression of CCR5,
ST2, CD25, BATF, IL10, GITR, LRRC32 (GARP), and CCR8,
compared to blood CD25HIFOXP3+ Tregs, while decidual
PD1HI Tregs had increased expression of IL-10, IFNɣ, and
CCR5, compared to blood PD1HI Tregs. Interestingly, first-
trimester decidual TIGIT+ Tregs increased expression of IL-
10, IFNɣ, LRRC32, and GZMA, while term pregnancy TIGIT+
Tregs had increased expression of, for example, VEGFA,
IFNɣ, GITR, and CD39 (Figures S6B and S6C). Flow cytometric
analysis of freshly isolated Tregs from all tissues confirmed dif-
ferential protein expression of key mRNAs identified here (Fig-
ure S7). The increased expression of a variety of cytokines
(e.g., IL-10, IFNɣ), chemokines (e.g., CCR5, CCR8), activation
markers (e.g., HLA-DR, GZMA), and co-inhibitory genes and
molecules (e.g., CD39, TIM3, LRRC32) on decidual Tregs
may suggest increased Treg activation and suppressive func-
tion in decidual tissue to regulate inflammatory responses at
the maternal fetal interface.
EVTs and Decidual Macrophages Increase Treg
Proportions during Co-culture
Previous studies demonstrated that EVTs directly increased
FOXP3 levels in CD4+CD25HI Tregs during co-culture (Svens-
son-Arvelund et al., 2015; Tilburgs et al., 2015) and that
decidual macrophages favored Treg differentiation (Wang
et al., 2016). To investigate the capacity of EVTs and decidual
macrophages to increase the three Treg types, EVTs and
Figure 3. Decidual Tregs Influence Cyto-
kine Production by CD4+ and CD8+ Teffs
(A–F) Graphs depict absolute change (D) in
percentage of IFNɣ+ (A and D), TNFɑ+ (B and E),
and IL-10+ (C and F) decidual CD4+ Teffs
(top panels) and decidual CD8+ Teffs (bottom
panels) upon addition of sample-matched CD25HI,
PD1HI, or TIGIT+ T cells, compared to CD4+ Teffs
and CD8+ Teffs cultured alone. Bars represent
median and interquartile range; n = 4–5; *p < 0.05,
**p < 0.01.
See also Figure S5.
decidual macrophages isolated from
first-trimester placental tissue were co-
cultured with naive CD4+ pTs for
3 days as described previously (Tilburgs
et al., 2015). Co-culture of EVTs or
decidual macrophages with CD4+ pTs
significantly increased the proportion
of FOXP3+ and HELIOS+ Tregs (Fig-
ure 5A). EVTs, but not decidual macro-
phages, also increased the proportion
of PD1HI Tregs, while neither EVTs nor
decidual macrophages changed the
TIGIT+ population (Figure 5A). To deter-
mine whether EVTs and decidual mac-
rophages increased Treg proportions
through cell-cell contact or by secretion
of soluble factors, EVTs or decidual
macrophages and CD4+ pTs were co-cultured in a transwell
system. Separation of EVTs or decidual macrophages from
CD4+ pTs by a transwell membrane resulted in a small but
not significant decrease in the induction of FOXP3+ and
HELIOS+ cells by EVTs and decidual macrophages (Figures
5B and 5C), suggesting that both cell-cell contact and
soluble factors may play a role in the induction of FOXP3+
cells by EVTs and decidual macrophages. In contrast, when
EVTs and CD4+ pTs were separated by a transwell mem-
brane, the increase in the proportion of PD1HI cells was abro-
gated, demonstrating that cell-cell contact is required here
(Figure 5B).
To further investigate the mechanisms by which EVTs and
decidual macrophages increase Treg proportions, additional
cell cultures were established where EVTs or decidual macro-
phages were co-incubated with CD4+ pTs in the presence of
IgG controls and blocking antibodies for a panel of co-inhibi-
tory molecules and anti-inflammatory cytokines. The increase
in FOXP3+ cells was not reversed by addition of any of the
blocking antibodies tested in EVT co-cultures (TCR coreceptor
CD3; HLA-C; HLA-G receptor ILT2; HLA-G; coinhibitory
molecule PDL1; and the immune modulatory cytokine TGFb)
(Figure 5D) and decidual macrophage co-cultures (ILT2,
HLA-DR, PDL1, TGFb, IL-10 receptor [IL-10R]) (Figure 5E).
Interestingly, addition of HLA-C and CD3 antibodies signifi-
cantly inhibited the induction of PD1HI cells by EVTs (Figure 5F),
while blocking HLA-G interactions resulted in a small but not
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significant reduction. Blocking ILT2, PDL1, and TGFb in the
EVTs and CD4+ T cell co-cultures did not significantly affect
induction of PD1HI cells by EVTs (Figure 5F). The question of
whether placental viral infections alter Treg induction or Treg
stability and thereby exacerbate placental inflammation is clin-
ically important. EVTs were infected with human cytomegalovi-
ruses (HCMVs), the most common pathogen to infect the
placenta and a major cause of congenital disease (Crespo
et al., 2016). Interestingly, no differences were observed in
the capacity of healthy or HCMV-infected EVTs to increase
CD25HIFOXP3+ and PD1HI Treg proportions (Figure 5G).
Collectively, these results suggest that Tregs can locally be
induced by EVTs and decidual macrophages and that anti-
gen-specificity may be involved.
DISCUSSION
Modulation of co-inhibitory molecules and Tregs function has
exceptional therapeutic potential for treatment of a wide vari-
Figure 4. Gene Expression Profiles of CD4+
Tregs and Teffs
(A and B) K-means clustering identified two clus-
ters of genes (A and B) that significantly correlate
their mRNA expression pattern among CD25HI,
PD1HI, TIGIT+, and Teffs. Blood (left panels),
decidua 6–12 weeks (middle panels), and
d.parietalis >37 weeks (right panels) are depicted.
(C–E) Heatmaps depict differentially expressed
genes identified in these clusters in blood (C),
decidua 6–12 weeks (D), and d.parietalis >37
weeks (E). n = 4 for all T cell types.
See also Figures S6 and S7.
ety of inflammatory disorders, including
cancer, chronic infection, autoimmune
disease, and pregnancy complications.
This study has refined our view of Treg
populations at the maternal-fetal inter-
face by presenting phenotypic and func-
tional data of three Treg populations,
CD25HIFOXP3+, PD1HIFOXP3-IL-10+,
and TIGIT+FOXP3dim Tregs, found in
decidual tissues of human first-trimester
and term pregnancy. Functional sup-
pression assays confirmed that decidual
CD25HIFOXP3+ Tregs suppress prolifer-
ation and production of IFNg and TNFɑ
by CD4+ and CD8+ Teffs. Decidual
PD1HI Tregs were shown to suppress
proliferation of CD4+ (but not CD8+)
Teffs in an IL-10-dependent manner.
PD1HI Tregs also increased expression
of IL-10 in Teffs, possibly resulting in a
positive feedback loop sustaining Teff
suppression while inducing additional
IL-10 secreting Tregs.
Decidual TIGIT+ cells significantly in-
hibited CD4+ T cell proliferation but did
not influence CD8+ Teff proliferation or cytokine production,
suggesting TIGIT+ Tregs only have limited capacity to sup-
press T cells, but their ability to suppress other cell types
(e. g. APCs) was not investigated here. Further analysis of
gene and protein expression of all Treg types in blood and
decidua clearly separated the three Treg types and revealed
that many immune regulatory molecules (e. g. CTLA4, ST2,
LRRC32, GITR, IFNg, and IL-10) have increased expression
in decidua compared to blood. Thus, decidual Tregs are highly
activated and have the potential to influence immune re-
sponses through a variety of molecular pathways and cellular
targets. Of importance here is further investigation into the
contribution of decidual Treg types on the modulation of
decidual CD8+ effector-memory T cells, which were shown
to have signatures of T cell activation and dysfunction (van
der Zwan et al., 2018).
Most interesting here is the discovery of the role of HLA-C
in the induction of PD1HI Tregs by EVT. EVTs, but not decidual
macrophages, have the capacity to directly increase PD1HI
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Tregs through cell-cell contact. Blocking of the TCR co-recep-
tor CD3 or HLA-C in these EVT and CD4 T cell co-cultures
significantly reduced this increase, suggesting that antigen-
specificity may be involved. Although it is well established
that CD4+ T cells recognize major histocompatibility complex
(MHC) class II molecules, MHC class I-restricted CD4+
T cells have been reported (Boyle et al., 2004). Decidual
PD1HI Tregs somewhat resemble Tr1 cells that have been
extensively characterized in murine tissues (Yu et al., 2017)
and human peripheral blood (Gagliani et al., 2013; Kunicki
et al., 2018). Their similarities include the high expression of
Figure 5. EVTs and Decidual Macrophages
Increase Treg Proportions
(A) CD4+ T cells were cultured alone or in the
presence of EVTs or decidual macrophages for
3 days. Cells were analyzed for the percentage of
FOXP3+, HELIOS+, PD1HI, and TIGIT+ cells as
described in Figures S1A and S1B.
(B) CD4+ T cells were cultured alone, with EVTs, or
with EVTs separated by a transwell membrane for
3 days and analyzed for the percentage of
FOXP3+, HELIOS+, and PD1HI cells.
(C) CD4+ T cells were cultured alone, with
decidual macrophages, or with decidual macro-
phages separated by a transwell membrane for
3 days and analyzed for the percentage of
FOXP3+ cells.
(D–F) CD4+ T cells were cultured alone or with
EVTs or decidual macrophages in the presence
of IgG, or blocking antibodies for CD3, HLA-C,
ILT2, HLA-G, PDL1, TGFb, and IL-10R and
analyzed for the percentage of FOXP3+ (D and E)
and PD1HI (F) cells.
(G) CD4+ T cells were cultured alone or with
EVTs or HCMV-infected EVTs and analyzed
for the percentage of FOXP3+ and PD1HI cells.
Bars represent median and interquartile range;
n = 8–14; *p < 0.05; **p < 0.01; ***p < 0.005.
PD1, IL-10, IFNɣ, and granzymes and
the lack of FOXP3 expression. In
contrast to Tr1 cells that were shown
to depend on the ILT2-HLA-G path-
way for their induction (Gregori et al.,
2009), induction of PD1HI cells by EVTs
was not dependent on the HLA-G re-
ceptor ILT2, while directly blocking
HLA-G during the EVT and CD4 T cell
co-culture resulted in a small but not
significant decrease of PD1HI Tregs in-
duction. Tr1 cells were also shown to
be induced by DC-10 through IL-10
secretion and interaction of HLA-G and
ILT4 (Gregori et al., 2010). Thus, other
decidual cell types such as HLA-G+
DC-10, that are found in decidual tis-
sues may contribute to induction of the
PD1HI Tregs described here (Amodio
et al., 2013). The main mechanisms
of Tr1-mediated suppression are the secretion of IL-10 and
killing of APCs by granzyme B (Passerini et al., 2011). The
expression of perforin and granzymes in first-trimester decidua
PD1HI Tregs may suggest they can also diminish APC activity
using this pathway. Tr1 cells were identified in HLA-mis-
matched fetal liver hematopoietic stem cell transplant (HSCT)
patients and were shown to suppress allogeneic responses
in transplant patients and prevent autoimmune responses
(Pot et al., 2011; Roncarolo and Battaglia, 2007). While the
specificity of decidual PD1HI Tregs remains unknown, the
requirement for direct cell-cell contact with EVTs for their
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induction, as well as the role for the TCR co-receptor CD3,
may provoke speculation that decidual PD1HIIL-10 Tregs
have specificity for fetal allo-antigens expressed by EVTs
(e.g., HLA-C). In comparison with decidual PD1HI Tregs,
decidual CD25HIFOXP3+ Tregs had an increased capacity
to suppress proliferation and a more potent capacity to
suppress IFNɣ and TNFɑ production by CD4+ and CD8+
Teffs. Thus, the mechanisms of suppression utilized by
CD25HIFOXP3+ Tregs and PD1HI Tregs as well as the
effects on their cellular targets are inherently different. The
increased levels of co-inhibitory proteins and/or mRNAs
(e.g., CTLA-4, GITR, CD39, ST2, LRRC32) expressed by
decidual CD25HIFOXP3+ Tregs compared to blood CD25HI
FOXP3+ Tregs suggests increased Treg activation and sup-
pressive function in decidual tissue to regulate inflamma-
tion at the maternal-fetal interface. Furthermore, it demon-
strates that decidual Tregs may utilize distinct molecular
mechanisms of immune modulation against a variety of cellular
targets beyond the inhibition of CD4+ and CD8+ Teff
responses.
The question of whether decidual Tregs are nTregs gener-
ated in the thymus with specificity for self-antigens or iTregs
generated in the periphery with specificity for paternal
antigens is immunologically interesting and of clinical rele-
vance. It was previously reported that HELIOS is a marker
of thymic-derived Tregs, while HELIOSneg Tregs were induced
from FOXP3neg T cells in the periphery (Thornton et al., 2010).
HELIOS and FOXP3 double-positive Tregs had increased
suppressive capacity, more stable FOXP3 expression, and
dissimilar TCR repertoire compared to HELIOSnegFOXP3+
Tregs (Sebastian et al., 2016; Thornton et al., 2019). Instability
of HELIOS-deficient Tregs was also associated with conver-
sion to a T-effector phenotype and enhanced antitumor immu-
nity (Nakagawa et al., 2016), and HELIOS was shown to
control certain aspects of Treg-suppressive function, differen-
tiation, and survival (Sebastian et al., 2016). However, the lack
of HELIOS expression does not exclusively identify human
iTregs (Himmel et al., 2013). Here, we demonstrate that hu-
man decidual CD25HIFOXP3+ Tregs have a high expression
of HELIOS, which reduces in term pregnancy decidua as
well as in cases of miscarriage, as was shown previously
(Inada et al., 2015). Furthermore, we demonstrate that co-
culture of CD4+ T cells with EVTs or decidual macrophages
both significantly increased the expression of FOXP3 and
HELIOS, advocating for either a local expansion of FOXP3+
and HELIOS+ nTregs or a possible de novo induction of
FOXP3+ and HELIOS+ iTregs. The increased suppressive
capacity of first-trimester CD25HI Tregs compared to term
pregnancy CD25HI cells aligns with the observation that
HELIOS expression increases and/or stabilizes Treg function.
Clonally expanded CD4+CD25HICD127–CD45RA– Treg popu-
lations were observed in term pregnancy decidua (Tsuda
et al., 2018), and preferential recruitment of fetus-specific
CD25HIFOXP3+ Tregs from the maternal peripheral blood
to the maternal-fetal interface has been suggested to
occur in human pregnancy (Tilburgs et al., 2008). Furthermore,
CD4+CD25HI Tregs had increased suppressive function when
they were isolated from decidual tissue with a maternal-fetal
HLA-C mismatch compared to an HLA-C match (Tilburgs
et al., 2009). In neither of these studies was HELIOS ex-
pression investigated, but an explanation to align these
observations may be that CD25HIFOXP3+ Tregs are a mixed
population of self-specific nTregs and fetus-specific iTregs.
Another explanation may suggest that an increased induction
of other iTreg types (e.g., PD1HI Tregs) induced in response
to fetal allo-antigens may indirectly increase or enhance
CD25HIFOXP3+ Tregs stability and/or function through secre-
tion of immune-suppressive IL-10 and/or other factors.
Because of the intracellular nature of HELIOS and the lack
of other markers to distinguish CD25HIFOXP3+ nTregs
from iTregs, it is technically not possible to investigate func-
tional differences between these cells from human tissues. A
further focus on the mechanisms by which both CD25HI
FOXP3+ and PD1HIIL-10 Tregs are induced by EVTs and
decidual macrophages at the maternal-fetal interface as well
as the effects of their mutual interactions will contribute to
answering burning questions on their origin and antigen
specificity.
In contrast to our expectations, infection of EVTs with
HCMVs did not diminish the ability of EVTs to increase CD25HI
FOXP3+ and PD1HI Tregs, suggesting that HCMV infection
does not alter the capacity of EVTs to promote immune toler-
ance. This is in line with a previous observation that decidual
natural killer (NK) cells degranulated in response to HCMV-in-
fected maternal decidual stromal cells, but not in response to
HCMV-infected EVTs, suggesting that immune tolerance is
maintained at the expense of efficient clearance of HCMV
infection (Crespo et al., 2016). Relevance of the distinct Treg
populations should be addressed by studying their presence
and functionality in cases of pregnancy complications.
Decreased proportions of decidual CD4+CD25HI FOXP3+ and
HELIOS+ Tregs were associated with spontaneous recurrent
miscarriage (Inada et al., 2015, 2013) and preeclampsia (Stein-
born et al., 2008; Wagner et al., 2016; Zhang et al., 2018). The
detailed phenotypic characterization, combined with gene
expression and extensive functional analysis of multiple Treg
populations as presented here, provides a strong platform
for guiding analysis of altered Tregs in clinical conditions for
which no systematic functional Treg characterization has
been performed.
This study provides strong evidence that multiple types of
decidual Tregs, including nTregs and iTregs, play a key role
in maintaining maternal-fetal immune tolerance during preg-
nancy. Moreover, the decidual microenvironment contains cell
types, particularly EVTs and decidual macrophages, which
have mechanisms to stabilize and expand Treg populations.
Of importance here is the data demonstrating that blocking
the TCR co-receptor CD3 as well as HLA-C during EVT -
CD4 T cell co-cultures inhibited the increase in PD1HI Tregs,
suggesting antigen specificity. Further, characterization of
decidual Tregs and Teffs in placental materials obtained after
spontaneous preterm birth, preeclampsia, and intrauterine in-
fections will accelerate discovery of therapeutic targets to pre-
vent and cure these severe pregnancy complications, as is
underway for treatment of many types of cancer and autoim-
mune diseases.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD3-PerCP; UCHT1 Biolegend RRID:AB_893300; Cat #300427
CD3-LEAF purified; SPV-T3B ThermoFisher RRID:AB_2532975; Cat #07-0303
CD4-PerCp; SK3 Biolegend RRID:AB_2563326; Cat #344624
CD4-Alexa700; SK3 Biolegend RRID:AB_2563150; Cat #344622
CD8-APC; SK1 Biolegend RRID:AB_2616624; Cat #980904
CD8-Alexa700; SK1 Biolegend RRID:AB_2562790; Cat #344724
CD8-Pacific Orange; 3B5 Invitrogen RRID:AB_10372066; Cat #MHCD0830
CD14-PerCp; HCD14 Biolegend RRID:AB_2564058; Cat #301847
CD14-PE-TexasRed; TuK4 Invitrogen RRID:AB_10373552; Cat #MHCD1417
CD25-PE; 2A3 BD Biosciences RRID:AB_2783790; Cat #341011
CD39-FITC; A1 Biolegend RRID:AB_940423; Cat #328205
CD45-Pacific Orange; HI30 Invitrogen RRID:AB_10376143; Cat #MHCD4530
CD45-APC; HI30 Biolegend RRID:AB_2562049; Cat #304037
CD45-PerCp; HI30 Biolegend RRID:AB_893341; Cat #304025
CD45RA-Alexa700; HI100 Biolegend RRID:AB_493762; Cat #304119
CD56-PE; HCD56 Biolegend RRID:AB_604093; Cat #318305
CTLA4-PE-Cy7; BNI3 Biolegend RRID:AB_2632876; Cat #369614
EGFR1-FITC; AY13 Biolegend RRID:AB_11124324; Cat #352907
FOXP3-Pacific Blue; 259D BioLegend RRID:AB_940354; Cat #320215
GITR-APC; DT5D3 Milteny Biotec RRID:AB_2751597; Cat #130-118-997
HELIOS-Alexa488; 22F6 Biolegend RRID:AB_10645334; Cat #137213
HLA-DR-LEAF purified; L243 Biolegend RRID:AB_314680; Cat #307602
HLA-G-PE; MEM/G9 Abcam RRID:AB_448029; Cat #ab24384
HLA-G-LEAF purified; 87G Biolegend RRID:AB_10641840; Cat #335904
IFNg-APC; B27 Biolegend RRID:AB_315443; Cat #506510
IL-10-PE-Cy7; JES3-9D7 Biolegend RRID:AB_2280292; Cat #501419
IL-10R-LEAF purified; 3F9 Biolegend RRID:AB_314737; Cat #308805
IL-2-PE; MQ1-17H12 Biolegend RRID:AB_315093; Cat #500306
ILT2-LEAF purified; GHI/75 Biolegend RRID:AB_1089089; Cat #333702
LRRC32-APC; 7B11 Biolegend RRID:AB_10896059; Cat #352505
PD1-PE-Cy7; EH12.1 BD Biosciences RRID:AB_10611585; Cat #561272
PDL1-LEAF purified; 29E.2A3 Biolegend RRID:AB_940370; Cat #329701
TGFb1-LEAF purified; 19D8 Biolegend RRID:AB_2561694; Cat #521703
TIGIT-APC; MBSA43 eBioscience RRID:AB_2573305; Cat #17-9500-42
TIGIT-PerCp-eFlour710; MBSA43 eBioscience RRID:AB_10853679; Cat #46-9500-42
TIM3-FITC; F38-2E2 Biolegend RRID:AB_2563936; Cat #345021
TNFa- Pacific Blue; MAb11 Biolegend RRID:AB_528965; Cat #502920
Bacterial and Virus Strains
HCMV-AD169-GFP (IE-1-GFP) Donald Coen, Harvard
Medical School
N/A
Chemicals, Peptides, and Recombinant Proteins
Recombinant human IL-2 Peprotech Cat #200-02
Recombinant human EGF Peprotech Cat #AF-100-15
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tamara
Tilburgs (tilburgs@fas.harvard.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Discarded human placental and decidual materials (gestational age 6-12 weeks) were obtained from women undergoing elective
pregnancy termination at a local reproductive health clinic. Term placental tissues (gestational age > 37 weeks) were obtained
from healthy women after uncomplicated pregnancy at term delivered by elective cesarean section or uncomplicated spontaneous
vaginal delivery at Tufts Medical Center. All tissues were visually inspected for signs of excessive inflammation (including
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Fibronectin Corning Cat #354008
Insulin-Transferrin-Selenium (ITS-G) (100X) GIBCO Cat #41400-045
Human gonadotropic hormone (HcG) Sigma-Aldrich Cat #C1063
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat #P1585
Ionomycin Sigma Cat #I9657
Collagenase type IV Sigma-Aldrich Cat #C5138
DNase I Sigma Cat #DN25
Percoll GE Healthcare Cat #17-5445-02
DNA suspension buffer TEKnova Cat #T0220
Human AB serum Corning Cat #35060CI
New Born Calf Serum GIBCO Cat #16010159
Exonuclease I New England BioLabs Cat #M0568S
Critical Commercial Assays
RosetteSep human CD4+ enrichment cocktail Stem Cell Technologies Cat #15022
Dynabeads Human T-Activator CD3/CD28 Thermofisher Cat #111.31D
CytoFix/CytoPermTM Plus kit BD Biosciences Cat #555028
RNAeasy Micro Kit Qiagan Cat #74004
AffinityScript QPCR cDNA Synthesis Kit Agilent Cat #600559
PerfeCTa SYBR Green SuperMix Low ROX QuantaBio Cat #:95056-100
BioMark Fluidigm QPCR 96.96 chip Fluidigm Cat #:BMK-M-96.96
Fluidigm PreAmp Master mix Fluidigm Cat #:100-5580
DNA binding dye sample and assay loading reagent kit Fluidigm Cat #: 100-3415
SsoFast EvaGreen supermix with low ROX BioRad Cat #: 1725210
Oligonucleotides
See Table S1 for primers used in this study
Software and Algorithms
BD FACSDIVA Software BD Biosciences http://www.bdbiosciences.com/us/
instruments/research/software/flow-
cytometry-acquisition/bd-facsdiva-
software/m/111112/features
FlowJo Software FlowJo https://www.flowjo.com/
Prism GraphPad software Prism https://www.graphpad.com/
scientific-software/prism/
Fluidigm BioMark Real-Time PCR analysis software Fluidigm https://www.fluidigm.com/software
GenePattern/ Express Cluster V1.3 software GenePattern https://cloud.genepattern.org/gp
http://cbdm.hms.harvard.edu/resources.htm
Microsoft Excel Microsoft https://products.office.com/en-US/excel
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discoloration, large infarctions and foul odor) and only healthy tissues were used for further processing. Peripheral blood leukocytes
were isolated from discarded leukopacks from healthy volunteer blood donors at theMassachusetts General Hospital in Boston, MA.
All human tissue used for this research was de-identified, discarded clinical material. No clinical information including the fetal sex
and sex of blood donors was available for analysis. The Committee on the Use of Human Subjects (the Harvard IRB) determined that
this use of placental and decidual material is Not Human Subjects Research. Term placental tissue was collected under a protocol
approved by Tufts Health Sciences IRB. All procedures to process these human blood and tissuesmaterials are described inmethod
details.
METHOD DETAILS
Isolation of T cells and decidual macrophages
The procedures to isolate lymphocytes and EVT have recently been described (Tilburgs et al., 2015) and are also described in detail
hereafter. To isolate 1st trimester decidual lymphocytes, villous and decidual tissues from elective pregnancy terminations were
macroscopically identified and separated. Decidua parietalis from term pregnancy was collected by removing the amnion and deli-
cately scraping the decidua parietalis from the chorion. Decidua basalis wasmacroscopically dissected from thematernal side of the
placenta. Collected decidual tissues were washed with PBS, minced and thereafter digested with 0.1% collagenase type IV and
0.01% DNase I (Sigma-Aldrich) gently shaking in a water bath for 75 min at 37C. After digestion, released lymphocytes from 1st
trimester and term placenta decidua were washed with RPMI 1640 (Life technologies) containing 10% FBS (Atlanta Biologicals)
for 8 min at 1800 rpm and filtered through 100 mm, 70 mm and 40 mm sieves (BD, Labware; NJ). Lymphocytes were dissolved in
20 mL 1.023 g/ml Percoll (GE Healthcare) and layered on a Percoll gradient (10 mL 1.080 g/ml; 15ml 1.053 g/ml) for density gradient
centrifugation (25min, 2000rpm). Decidual lymphocytes were isolated from the 1.080 – 1.053 g/ml interface, and decidual macro-
phages were isolated from the 1.053 – 1.023 g/ml interface. Cells were washed twice with RPMI and directly stained for flow cyto-
metric analysis on a BD LSR-II or for FACS sort on a BD FACS ARIA-II. Peripheral blood CD4+ T cells were isolated using a Roset-
teSep human CD4+ enrichment cocktail (StemCell Technologies) followed by Ficoll (GE Healthcare) density gradient centrifugation
(20 min, 2000 rpm).
Flow Cytometry
Antibodies used for flow cytometry are listed in the Key Resources Table. For surface staining, cells were stained for 30 min on ice in
PBS 1%NCS. For intracellular staining, cells were fixed and permeabilized using the eBioscience FOXP3 staining kit (eBiosciences).
For detection of intracellular cytokines, CD4+ T cells were stimulated for 6 hours with phorbol 12-myristate 13-acetate (PMA; 1 mg/ml;
Sigma) and Ionomycin (1 mg/ml; Sigma), and Golgistop was added for the last 4 hours (1 ml/ml; BD Biosciences). Cells were fixed and
permeabilized using the BD CytoFix/CytoPerm kit (BV Biosciences). Acquisition and analysis was performed on a LSR-II (BD) using
FACS Diva software. tSNE analysis was performed using FlowJo 10 software.
Suppression of T cell proliferation assay
Purified decidual or peripheral blood CD4+ T cells were sorted on a BD FACS aria into four fractions (CD4+CD25HI, CD4+PD1HI,
CD4+TIGIT+ and CD4+ Teff) according to the gating strategy described in Figure S1. Decidual CD8+ T cells were obtained from
the same decidual sample. For CFSE labeling CD4+ Teff and CD8+ cells were resuspended in PBS at a concentration of 0.2 -
1.0 x106 cells per ml. CFSE (Invitrogen) was added in a 1:2500 dilution and cells were incubated for 5 mins in a water bath at
37C. Cells were washed with X-VIVO 10 supplemented with 50U IL-2 and 5% human AB serum (Corning) for 8 min at 1800 rpm.
Cells were resuspended at 0.4 x106 cells per ml in X-VIVO 10 supplemented with 50U IL-2 and 5% human AB serum. Treg were
cultured with the CFSE-labeled Teff in a 1:2 ratio of 20.000 Treg: 40.000 Teff cells, with the addition of Dynabeads Human T-Acti-
vator CD3/CD28 (1 ml/ml). After four days, cells were collected and stained for CD4-PerCP, CD8-Alexa700 and CD45-PacificOrange.
CFSE dilution of CD4+Teff and CD8+ T cells was analyzed using the proliferation analysis tool of FlowJo v7.6.5 software. The per-
centage of undivided cells (generation 0) was calculated based on the total number of cells. The division index was calculated by
FlowJo software and reflects the average number of divisions per cell.
Suppression of T cell cytokine production assay
Purified decidual CD4+CD25HI, CD4+PD1HI, CD4+TIGIT+, CD4+ Teff and CD8+ T cells were obtained as described above (Fig-
ure S1). CD4+ Teff cells were labeled with CFSE (Invitrogen) and CD8+ cells were labeled with CD45-Alexa700. Treg were cultured
with CD4+ and CD8+ Teff in a 1:1:1 ratio (20.000 Treg: 20.000 CFSE+ CD4+ Teff: 20.000 Alexa700+ CD8+ Teff). Control cultures
without Treg contained CD4+ and CD8+ Teff in a 1:1 ratio (30.000 CFSE+ CD4+ Teff: 30.000 Alexa700+ CD8+ Teff). CD3/CD28
Dynabeads (1 ml/ml) were added to all cultures and after three days, cells were re-stimulated with 2.5 ng/mL PMA in combination
with 0.1 mg/mL ionomycin for 6h in the presence of 1 mg/mL GolgiStop (BD Bioscience). Cells were collected and stained for cell
surface expression of CD4-PerCP, CD8-Alexa700, CD45-PacificOrange and intracellular expression of IL-10, IFNg and TNFa
upon fixation and permeabilization (CytoFix/CytoPermTM Plus kit (BD)). Acquisition was performed on an LSR-II (BD) using FACS
Diva software for analysis following the gating strategy shown in (Figure S4).
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RNA isolation and QPCR chip analysis
Purified CD4+ T cells from four samples of blood, decidua 6-12wk and d.parietalis > 37wk (Figure S1A) were resorted into four types
CD4+CD25HI, CD4+PD1HI, CD4+TIGIT+ and CD4+ Teff (Figure S1B) and collected directly into 600 mL Trizol reagent (Life technol-
ogies) supplemented with 0.5 mL glycogen (20mg/ml; Affymetrix) and stored at 80C until RNA isolation. Total RNA was isolated
using the RNAeasy Micro Kit (QIAGEN) per manufacturer’s instruction. RNA was analyzed on a Nanodrop to determine RNA yield
and integrity. RNA quality of all samples was further confirmed by performing a QPCR analysis for GAPDH and FOXP3 expression.
In short: RNA was reverse transcribed with Stratagene’s AffinityScript QPCR. cDNA Synthesis Kit and amplification of specific PCR
products for FOXP3 and GAPDHwere detected using the PerfeCTa SYBRGreen Super Mix with Low ROX (QuantaBio) in duplicates.
Subsequently, high quality samples were run in duplicate on the BioMark FluidigmQPCR 96.96 chip. 1.25ml DNAwas pre-amplified
in a 96-well plate using the Fluidigm PreAmp Master mix combined with 500nM forward and reverse primer of each primer pair
(2min at 95C, 10 thermal cycles of 15sec at 95Cand 4min at 60C) (primers are listed in Table S1). Exonuclease treatment to remove
unincorporated primers was carried out using the Exonuclease I at 40U/ml (New England BioLabs). 2ml of the Exonuclease I dilution
was added to each preamplification reaction and incubated in a thermal cycler for 30min at 37C and 15min 80C. A 5-fold dilution
was prepared in TE buffer (10mM Tris-HCl, 1.0mM EDTA, TEKnova, PN T0224). Sample pre-mix for the 48 samples was prepared
using 2ml of the prepared cDNA with 20X DNA binding dye sample loading reagent (Fluidigm) and 2X SsoFast EvaGreen supermix
with low ROX (Bio-Rad). The assay mix was prepared in a separate 96-well plate consisting of 2X assay loading reagent, 1X DNA
suspension buffer and 100mM of mixed forward and reverse primers. Chips were primed, loaded with both assay and sample mix
and run on BioMark readout instruments as described by the manufacturer, at Harvard University’s core facility. Biomark data
were processed using Fluidigm Biomark software. Quality control was based on EvaGreen reagent allowing for detection of unspe-
cific PCR product and formation of primer dimers using the BioMark software. Samples of failed reactions were automatically
excluded by the software. The resulting values for 66 primers of 48 samples were normalized by subtracting CT values for GAPDH
(DCT) and subsequent conversion into fold-change values relative to the median peripheral blood Teff (2DDCT). K-means cluster
analysis was performed using the fold-change values of the 66 genes in Express Cluster V1.3 in Genepattern https://cloud.
genepattern.org/gp. Differential expression of significantly correlating genes was based on K-means with a minimum of a 1.5-fold
change.
Isolation of EVT
Isolation of EVT and co-culture with CD4+ T cells was performed as described previously (Tilburgs et al., 2015) and are are also
described in detail hereafter. 1st trimester villous tissue was gently scraped from the basal membrane and the tissue was digested
for 8 min at 37C with a trypsin (0.2%) EDTA (0.02%) solution. Trypsin was quenched with DMEM/F12 medium containing 10%
Newborn Calf Serum (NCS) and 1%Pen/Strep (all fromGIBCO) and filtered over a gauzemesh. Filtrate waswashed once and layered
on Ficoll (GE Healthcare) for density gradient centrifugation (20min, 2000 rpm). Cells were collected, washed once and incubated for
20 min at 37C in a 30mm tissue culture dish for removal of macrophages. To establish untouched (free of antibody staining) EVT
cultures, for each sample the percentage CD45-HLA-G+ EVT was determined by FACS analysis for EGFR1, HLA-G and CD45. Sam-
ples with > 8%CD45-HLA-G+ cells were stained for CD45 and sorted for viable CD45- large trophoblast cells. 50.000 CD45-HLA-G+
EVT (calculated based on percentage HLA-G+ cells and total cell number) were plated in 48 well cell culture plates (Costar)
pre-coated with fibronectin (100 mL 20ng/ml 45min, BD), in DMEM/F12 (GIBCO) supplemented with 10% NCS, pen/strep and gluta-
mine, insulin, transferrin, selenium (GIBCO), 5ng/ml EGF (Peprotech) and 400 units human gonadotropic hormone (Sigma). Tropho-
blasts were incubated for 2h at 37C and thereafter washed 3 times to remove all non-adherent VT. Cultures resulted in 50%–80%
HLA-G+ EVT.
Co-culture of EVT, decidual macrophages and CD4+ T cells
50.000 EVT or decidual macrophages were co-incubated with 100.000 CD4+ pT from unrelated blood donors in X-Vivo10 medium
(Lonza), supplemented with 5% human AB serum and 50 units/ml IL-2 (Biolegend). For blocking experiments, LEAF-purified anti-
HLA-G (MoAb 87G; 20 mg/ml), anti-ILT2 (MoAb GHI/75; 20 mg/ml), anti-PDL1 (MoAb 29E.2A3; 20 mg/ml), anti-TGFb (MoAb 19D8;
25 mg/ml), anti-IL-10R (MoAb 3F9; 20 mg/ml), anti-HLA-DR (MoAb L243; 20 mg/ml), purified anti-HLA-C (MoAb DT-9; 10 mg/ml)
and IgG controls (all from Biolegend), or anti-CD3 (MoAb SPV-T3b; 25 mg/ml) (ThermoFisher Scientific) were added 30 min before
addition of CD4+ T cells. For transwell assays, 100.000 EVT or decidual macrophages were plated in 24 well cell culture plates
pre-coated with fibronectin, non-adherent EVT were removed and 200.000 CD4+ pT were added directly to the EVT and decidual
macrophage cultures or were added on top of the membrane after insertion of a 0.4 mM trans well membrane (Costar). CD4+ pT
were harvested after 60 hours and analyzed by Flow cytometry for CD45, CD4, CD25, PD1, TIGIT and intracellular FOXP3 and
HELIOS.
HCMV Infection of EVT
High titer virus stocks of HCMV-AD169-GFP (IE-1-GFP) (a gift from Prof. Donald Coen at Harvard Medical School) was obtained by
infecting Human Foreskin Fibroblasts (HFF) (ATCC) and collecting supernatants after 7 days. Supernatants were aliquoted and snap
frozen in liquid nitrogen until use. Primary EVT were infected with HCMV at an MOI of 2-4 for 12 hours (Crespo et al., 2016). Infected
cells were imaged in a Nikon EclipseTi fluorescence microscope at 20x magnification. HCMV infection of EVT reached > 80% at
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day 2, and no cytopathic effects on EVT were visible after HCMV (Crespo et al., 2016). For co-culture assays, HCMV infected cells
were washed twice after 12 hours of infection and 100.000 CD4+ pT were added. CD4+ pT were harvested after 48 hours and
analyzed by Flow cytometry for CD45, CD4, CD25, PD1, TIGIT and intracellular FOXP3.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data was analyzed using GraphPad Prism version 6.07 software. To determine differences between 2 paired groups a non-para-
metricWilcoxon Signed Rank test was performed (Figure S1E). To determine differences amongmore than 2 unpaired groups, a non-
parametric Kruskal-Wallis test with Dunn’s multiple comparison post-test was performed (Figures 1, 2, 3, and 5; Figures S3, S4, and
S7). For the Dunn’s post-test themean ranks were compared to control column A (Figures 2B2G and 3; Figures S4 and S7), column
B (Figures 5D5F) or with the mean rank of every column (Figures 1, 5A5C, and 5G; Figure S3). P values < 0.05 were considered to
denote significant differences. *p < 0.05; **p < 0.01; *** p < 0.005 are indicated within each figure. Sample size indicates biological
replicates of individual placental of blood cell isolates and are indicated indicted in each figure legend. Sample sizes were not deter-
mined beforehand.
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